Tarsus Pharmaceuticals, Inc. (TARS)

Nasdaq: TARS · Biological Products, (No Diagnostic Substances) · Irvine, CA · filing with the SEC since 2020

Full chart Alerts Compare

Grade6.3

◀ Past 5.6● Present 7.0▶ Future 6.0

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$451M+146.7%

Net income-$66.4M+42.5%

Earnings per share$-1.59+48.2%

Operating cash flow-$12.5M+85.0%

Cash$186M+91.2%

Debt$72.4M+0.8%

Shareholders’ equity$343M+53.0%

Shares, diluted41.8M+11.1%

Return on equity-19.3%

The recordfrom its filings

Filings in 2026129

Newest filingNov 5 · 4

Annual reportFeb 23, 2026

Quarterly reportNov 3, 2026

Next report due10-K by Mar 1

Insider sales, 12 months$20.0M

Insider buys, 12 months$0.00

Patents granted10

Filer categoryLarge accelerated filer

Trailing twelve months to Sep 2026Revenue $682MNet income -$702MCash from operations $49.9Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

1819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 5, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form 3

Insider holding, initial

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Nov 3, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 3, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Oct 13, 2026 · SEC EDGAR · Form 8-K/A

Current report, amended

Open the filing on sec.gov

Oct 13, 2026 · SEC EDGAR · Form S-3ASR

Shelf registration

Open the filing on sec.gov

Oct 13, 2026 · SEC EDGAR · Form S-3ASR

Shelf registration

Open the filing on sec.gov

Sep 17, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Sep 17, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Tarsus Pharmaceuticals, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Irvine, CA.

Newest on the record

Insider trade report on Nov 5. Before it, insider holding, initial on Nov 5.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 1, 2027.

About TARS

Tarsus Pharmaceuticals, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Irvine, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $451 million and a loss of $66 million (its filed statements).

IndustryBiological Products, (No Diagnostic Substances)

HeadquartersIrvine, CA

Business modelProduct business

ExchangeNasdaq

Filing since2020

Fiscal year endsDec 31

SEC number (CIK)1819790

Peers on fileFDMT, AUTL, ADPT, ADMA

Who runs it

Financial performance

In fiscal 2025 Tarsus Pharmaceuticals’s revenue was $451.4 million, up 146.7% from $183.0 million the year before. It made a net loss of $66.42 million.

Annual report, filed Feb 23, 2026.

Financial statements

The grade

Tarsus Pharmaceuticals grades 6.3 of 10 against its own industry, the 159 companies in Biological Products, (No Diagnostic Substances). Eight of the nine metrics are read as filed and one is an SI estimate, each with its reasoning.

◀ Past5.6

● Present7.0

▶ Future6.0

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton TARS · research, not advice